Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations, along with rearrangements across 361 genes from formalin-fixed, paraffin-embedded (FFPE) solid tumour tissue.

The test incorporates 3D genomics technology, leveraging the preservation of spatial proximity of rearranged and fused genes for a 100–1,000-fold signal amplification and detection of new breakpoints and fusion partners.

Aventa Genomics executive director Chris Roberts said: “In previously characterised tumour specimens from patients with no known actionable driver, the Aventa FusionPlus test detected potentially actionable variants in half of the cases.

“The increase in diagnostic yield from detecting actionable biomarkers FISH and RNA sequencing miss, we believe, will provide more treatment options and will facilitate improved patient management.”

The test helps detect biomarkers that are missed by conventional testing methods such as fluorescent in situ hybridisation and RNA sequencing, apart from actionable biomarkers.

Furthermore, it leverages analysis and reporting platforms to comprehensively assess the tumour.

The company uses its Clinical Laboratory Improvement Amendments-certified laboratory in Orlando, Florida, to perform testing services.

Aventa Genomics medical director Anthony Magliocco said: “The Aventa FusionPlus test is unique in the market and we believe it offers physicians a powerful new tool to reveal druggable targets and resolve diagnostic dilemmas.

“We are happy to make this innovative, clinically impactful, precision laboratory-developed diagnostic test available to treating physicians for the benefit of their patients.”

The company is a joint venture between Protean BioDiagnostics and Arima Genomics and offers 3D Genomics tools for identifying druggable targets.